Method of Redirecting T Cells to Treat HIV Infection
AssigneeThe Trustees of the University of Pennsylvania
InventorsJames L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
Claims25
A nucleic acid comprising a sequence encoding a membrane-bound chimeric receptor comprising a CD4 extracellular domain, a transmembrane domain, and a signaling domain, wherein the CD4 extracellular domain is capable of recognizing and binding a HIV infected cell.
2-10. (canceled)
A membrane-bound chimeric receptor comprising a CD4 extracellular domain, a transmembrane domain, and a signaling domain, wherein the CD4 extracellular domain is capable of recognizing and binding a HIV infected cell.
12-20.
A nucleic acid comprising a sequence encoding a chimeric antigen receptor (CAR) comprising a HIV-specific binding domain, a transmembrane domain, a costimulatory signaling region, and a signaling domain, wherein the HIV binding domain comprises an anti-HIV antibody or a fragment thereof.
34-35. (canceled)
(canceled)
42-43. (canceled)
Dependencies are inferred from the claim text.